Zuranolone Drug Asset Due Diligence Report 2026

This Zuranolone Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Zuranolone can convert its Small molecule drug profile and GABAA receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Zuranolone (query alias: Zuranolone)
Modality / target	Small molecule drug; GABAA receptor; GABAA receptor positive allosteric modulator
Highest global status	Approved
Originator	SAGE Therapeutics, Inc.
Active developers	SAGE Therapeutics, Inc., Biogen, Inc., BIOGEN NETHERLANDS BV

The MCP disease footprint includes Depressive Disorder, Major, Depressive Disorder, Depression, Postpartum. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06759558	Phase 2	Recruiting	6	Number of participants with treatment emergent adverse events (TEAEs) after starting zuranolone
NCT05655507	Phase 1	Completed	19	Plasma Concentrations of Zuranolone
NCT07398469	Not Applicable	Recruiting	200	Change From Baseline in the Edinburgh Postnatal Depression Scale (EPDS) Score at Day 15

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder

Phase 3; n=not disclosed; evaluation: Positive. Reported fields: Adverse Event: TEAEs = Of patients who experienced TEAEs, most reported mild or moderately severe events, and responders to zuranolone experienced improvements in depressive symptoms with initial and repeat treatment courses ; Adverse Event: TEAEs = Of patients who experienced TEAEs, most reported mild or moderately severe events, and responders to zuranolone experienced improvements in depressive symptoms with initial and repeat treatment courses

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder

Phase 3; n=543; evaluation: not stated. Reported fields: Change From Baseline in the 17-item HAM-D Total Score at Day 15(Least Squares Mean) = -12.3 score on a scale (Standard Error, 0.50); Change From Baseline in the 17-item HAM-D Total Score at Day 15(Least Squares Mean): Least Squares (LS) Mean Difference = -1.7(95% CI, -3.1 to -0.3), P-Value = 0.0141; Change From Baseline in the 17-item HAM-D Total Score at Day 15(Least Squares Mean): Least Squares (LS) Mean Difference = -1.7(95% CI, -3.1 to -0.3), P-Value = 0.0141

A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder

Phase 3; n=440; evaluation: not stated. Reported fields: Change From Baseline in the HAMD-17 Total Score at Day 3(Least Squares Mean) = -7.0 score on a scale (Standard Error, 0.38); Change From Baseline in the HAMD-17 Total Score at Day 3(Least Squares Mean): LS Mean Difference = -1.9(95% CI, -3.0 to -0.9), P-Value = 0.0004; Change From Baseline in the HAMD-17 Total Score at Day 3(Least Squares Mean) = -8.9 score on a scale (Standard Error, 0.39)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Zuranolone addresses Depressive Disorder, Major, Depressive Disorder, Depression, Postpartum. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-06-16	Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics	Approved	US$795.0M stated total
2020-11-27	Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders	Phase 3	US$1,525.0M upfront; US$1,600.0M milestones
2018-06-12	Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea	Phase 2	US$90.0M upfront; US$0.5M milestones; US$90.5M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO